GlassScriptPhysician profile
Eugene Orloff
NPI 1386731974
$3,637.07
in general payments reported to CMS, 2019-2025
21 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $148 · 2021: $378 · 2022: $857 · 2023: $428 · 2024: $746 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $776.70 | 2019-2024 | Myday Contact Lens, Misight Contact Lens |
| Novartis Pharmaceuticals Corporation | $613.09 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $463.95 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $418.84 | 2024-2025 | Eysuvis, Tryptyr, Precision 1 |
| Biotissue Holdings INC. | $332.62 | 2021-2023 | |
| Shire North American Group INC | $132.04 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $113.66 | 2022 | |
| Dompe US, INC. | $112.90 | 2024-2025 | Oxervate |
| Allergan, INC. | $109.33 | 2019-2021 | |
| Abbvie INC. | $89.22 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $73.41 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $65.42 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $63.34 | 2022-2025 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $59.62 | 2022 | |
| Aerie Pharmaceuticals, INC. | $43.10 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $41.95 | 2022-2023 | Tepezza |
| Optos, INC. | $39.95 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.07 | 2020-2021 | |
| Amgen INC. | $21.14 | 2025 | Tepezza |
| Spark Therapeutics, INC. | $19.82 | 2022 | |
| Ocular Therapeutix, INC. | $13.90 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Orloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.